Huntington Disease Clinical Trials

Find Huntington Disease Clinical Trials Near You

A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Effect of SRP-1005 in Subjects With Huntington's Disease (INSIGHTT)

Status: Recruiting
Location: See all (4) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

This is a first-in-human, multi-center trial studying the effects of SRP-1005 in participants with Huntington's disease (HD).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 21
Maximum Age: 70
Healthy Volunteers: f
View:

• Genetically confirmed diagnosis of huntingtin (HTT) cytosine-adenine-guanine repeat length ≥40.

• Participant has HD Integrated Staging System (HD-ISS) Stage 2 or Mild Stage 3. At screening, the participant must be classified with the Enroll-HD HD-ISS Modified Calculator as either Stage 2 or Mild Stage 3.

• Participants who are of childbearing potential, or with partners of childbearing potential, who are sexually active must agree to use a highly effective method of contraception throughout study participation, and for at least 90 days following the end of study.

Locations
Other Locations
Australia
Westmead Hospital
RECRUITING
Westmead
New Zealand
New Zealand Brain Research Institute
RECRUITING
Christchurch
Switzerland
Siloah AG
RECRUITING
Gümligen
United Kingdom
University Hospital of Wales
RECRUITING
Cardiff
Contact Information
Primary
Sarepta Therapeutics Inc., For Clinical Trial Information, Select Option 4
SareptAlly@sarepta.com
1-888-SAREPTA (1-888-727-3782)
Time Frame
Start Date: 2026-05-12
Estimated Completion Date: 2027-11-30
Participants
Target number of participants: 32
Treatments
Experimental: Cohort 1: SRP-1005 Dose 1
Participants will receive SRP-1005 or placebo.
Experimental: Cohort 2: SRP-1005 Dose 2
Participants will receive SRP-1005 or placebo.
Experimental: Cohort 3: SRP-1005 Dose 3
Participants will receive SRP-1005 or placebo.
Experimental: Cohort 4: SRP-1005 Dose 4
Participants will receive SRP-1005 or placebo.
Sponsors
Leads: Sarepta Therapeutics, Inc.

This content was sourced from clinicaltrials.gov